BOSTON--(BUSINESS WIRE)--Feb 25, 2026--
Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today the issuance of a patent in Japan covering core innovations underlying its Singularity Platform, the proprietary system that supports the company’s Singularity Suite of genetically engineered mouse models for single-domain antibody (sdAb) discovery. The patent strengthens Leveragen’s growing global intellectual property estate supporting long-term partnerships with pharmaceutical and biotechnology companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225850507/en/
Single-domain antibodies are increasingly important in modern biologics development due to their compact size, intrinsic stability, and modular architecture. These properties make sdAbs well suited for advanced therapeutic formats such as multispecific antibodies, antibody–drug conjugates (ADCs), mRNA-encoded antibodies, and cell and gene therapies, where conventional antibody formats can face structural, manufacturing, or delivery constraints.
The Singularity Platform was designed to address limitations of conventional transgenic models through targeted genome engineering and streamlined immune system architectures. Across the Singularity Suite, each model features a minimalist humoral immune system engineered to mount exclusive heavy-chain antibody immune responses, thereby concentrating immune selection on single-domain formats and enabling generation of high-diversity, high-fidelity sdAbs with strong stability, solubility, and developability.
Within the Singularity Suite, Singularity Sapiens is optimized for the discovery of fully human single-domain antibodies, eliminating the need for camelid immunization and downstream humanization. The model generates heavy-chain antibodies from a complete human VH repertoire precisely integrated into the endogenous mouse immunoglobulin heavy-chain locus, enabling in vivo selection of fully human sdAbs under native regulatory control.
The Singularity Suite extends these system-level design principles across a broad range of species-native single-domain antibody scaffolds, including human VH, human Vκ, alpaca VHH, shark VNAR, dog VH, cat VH, and mouse VH, providing partners with flexible access to diverse sdAb modalities within a unified discovery framework.
The issuance of Japan Patent No. JP7799706 provides independent validation of the novelty of the Singularity Platform and reinforces Leveragen’s ability to protect the core design principles underlying the Singularity Suite. Corresponding patent applications covering these innovations are currently pending in the United States, China, Europe, Canada, Australia, and other jurisdictions.
“The Singularity Platform was developed as a scalable foundation for single-domain antibody discovery,” said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen. “This patent issuance in Japan reinforces the originality of our system-level approach and strengthens our position as a differentiated provider of fully human and species-native single-domain antibody discovery technologies for pharmaceutical and biotechnology partners.”
Integrated with Leveragen’s sequence-first, high-throughput discovery workflows, the Singularity Suite supports efficient and reproducible generation of developable single-domain antibodies across a wide range of targets and applications, including human therapeutics, diagnostics, and animal health. The platforms are available through flexible licensing and service-based partnership models.
About Leveragen
Leveragen is a biotechnology company developing next-generation in vivo platforms for antibody discovery. Its proprietary platform portfolio includes the Singularity Suite for single-domain antibody discovery, the Universality Suite for common light-chain antibody discovery, and the Infinity Suite for full-length conventional antibody discovery. These platforms integrate locus-precise genome engineering, native regulatory control, and in vivo–derived antibody repertoires to enable efficient and reproducible antibody discovery across diverse modalities. Headquartered in the Greater Boston area, Leveragen partners with pharmaceutical and biotechnology companies world-wide to advance discovery programs across therapeutics, diagnostics, and animal health. For more information, please visit https://www.leveragen.com.
The Singularity Platform was designed to address limitations of conventional transgenic models through targeted genome engineering and streamlined immune system architectures. Across the Singularity Suite, each model features a minimalist humoral immune system engineered to mount exclusive heavy-chain antibody immune responses, thereby concentrating immune selection on single-domain formats and enabling generation of high-diversity, high-fidelity sdAbs with strong stability, solubility, and developability. Integrated with Leveragen’s sequence-first, high-throughput discovery workflows, the Singularity Suite supports efficient and reproducible generation of developable single-domain antibodies across a wide range of targets and applications, including human therapeutics, diagnostics, and animal health.
NEW YORK (AP) — Kamala Harris “wrote off rural America" during the 2024 presidential campaign and failed to attack Donald Trump with sufficient “negative firepower," according to a long-awaited post-election autopsy released on Thursday by the Democratic National Committee.
The committee's chair, Ken Martin, shared the 192-page report only after facing intense internal pressure from frustrated Democratic operatives concerned with his leadership. Martin had originally promised to release the autopsy, only to keep it under wraps for months because he was concerned it would be a distraction ahead of the midterms as Democrats mobilize to take back control of Congress.
On Tuesday, Martin apologized for his handling of the situation and conceded that the report was withheld because it “was not ready for primetime."
Although the autopsy criticizes Democrats' focus on “identity politics,” it sidesteps some of the most controversial elements of the 2024 campaign. The report does not address former President Joe Biden’s decision to seek reelection, the rushed selection of Harris to replace him on the ticket or the party's acrimonious divide over the war in Gaza.
“I am not proud of this product; it does not meet my standards, and it won’t meet your standards,” Martin wrote in an essay on Substack on Thursday. “I don’t endorse what’s in this report, or what’s left out of it. I could not in good faith put the DNC’s stamp of approval on it. But transparency is paramount.”
A spokesperson for Harris did not immediately respond to a request for comment.
The initial reaction from Democratic operatives was a mix of bafflement and anger over Martin's handling of the situation.
“Why not say this in 2024, or bring in more people to finish it, instead of turning this into the dumbest media cycle for 7-8 months?” Democratic strategist Steve Schale wrote on social media.
The postelection report, which was authored by Democratic consultant Paul Rivera, calls for “a renewed focus on the voters of Middle America and the South, who have come to believe they are not included in the Democratic vision of a stronger and more dynamic America for everyone.”
“Millions of Americans are suffering from poor access to healthcare, manufacturing and job losses, and a failing infrastructure, yet continue to be persuaded to vote against their best interests because they do not see themselves reflected in the America of the Democratic Party,” the report says.
The autopsy points to a reduction in support and training for Democratic state parties, voter registration shifts and “a persistent inability or unwillingness to listen to all voters.”
Thursday's release comes as Martin confronts a crisis of confidence among party officials who are increasingly concerned about the health of their political machine barely a year into his term. Some Democratic operatives have had informal discussions about recruiting a new chair, even though most believe that Martin’s job wasn't in serious jeopardy ahead of the midterm elections.
The report found that Harris and her allies failed to focus enough on Trump's negatives, especially his felony convictions. This was part of a broader criticism that Democrats' messaging is too focused on reason and winning arguments, “even in cycles when the electorate is defined by rage.”
“There was a decision in the 2024 Democratic leadership not to engage in negative advertising at the scale required,” the report states. “The Trump campaign and supportive Super PACs went full throttle against Vice President Harris, but there was not sufficient or similar negative firepower directed at Trump by Democrats.”
The report continues: “It was essential to prosecute a more effective case as to why Trump should have been disqualified from ever again taking office. The grounds were there, but the messaging did not make the case.”
Trump's attack on Harris' transgender policies were cited as a key contrast.
Specifically, the report suggested the Democratic nominee was “boxed” in by the Trump campaign's “very effective” ad that highlighted Harris' previous statement of support for taxpayer-funded gender-affirming surgeries for prison inmates.
Democratic pollsters believed that “if the Vice President would not change her position – and she did not – then there was nothing which would have worked as a response," the report said.
The report criticized Harris' outreach to key segments of America while condemning the party's focus on “identity politics.”
“Harris wrote off rural America, assuming urban/suburban margins would compensate. The math doesn’t work,” the report says. “You can’t lose rural areas by overwhelming margins and make it up elsewhere when rural voters are a significant share of the electorate. If Democrats are to reclaim leadership in the Heartland or the South, candidates must perform well in rural turf. Show up, listen, and then do it again.”
The report also references Democrats' underperformance with male voters of color.
“Male voters require direct engagement. The gender gap can be narrowed. Deploy male messengers, address economic concerns, and don’t assume identity politics will hold male voters of color,” it says.
President Donald Trump speaks during an event about loosening a federal refrigerant rule, in the Oval Office at the White House, Thursday, May 21, 2026, in Washington. (AP Photo/Jacquelyn Martin)
Former Vice President Kamala Harris speaks during a fireside chat on Thursday, May 7, 2026, in Las Vegas. (AP Photo/Ty ONeil)
FILE - Democratic National Committee chair Ken Martin speaks during an interview with The Associated Press at DNC headquarters, Jan. 12, 2026, in Washington. (AP Photo/Allison Robbert, File)
